Patient information for AUGMENTIN 1G TABLETS Including dosage instructions and possible side effects. En prophylaxie chirurgicale. Pour les interventions de durée inférieure à 1 heure, la dose recommandée d’AUGMENTIN est de 1000 mg/200 mg à 2000 mg/200 mg administrée à l’induction de l’anesthésie (pour obtenir des doses de 2000 mg/200 mg, utiliser une autre formulation IV d’AUGMENTIN). Augmentin by neměl být podáván pacientům spodezřením na infekční mononukleózu, neboť po léčbě amoxicilinem byly u těchto pacientů pozorovány morbiliformní vyrážky. Souběžné užívání allopurinolu při léčbě amoxicilinem může zvýšit pravděpodobnost výskytu alergické Augmentin(amoxicillin-clavulanate) is indicated for a wide range of infections. This comprehensive information is designed to help healthcare professionals in daily practice. Therapy can be started parenterally according the SPC of the IV formulation and continued with an oral preparation. 4.3 Contraindications Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients listed in section 6.1. Augmentin(amoxicillin-clavulanate) is indicated for a wide range of infections. This comprehensive information is designed to help healthcare professionals in daily practice Etiketa Augmentin tbl 14x1g na zadní stranu přípravku Rozměr: 180-185 x 85-88 mm Augmentin 1 g 14 potahovaných tablet 1 potahovaná tableta obsahuje: Amoxicillinum (ut amoxicillinum tríhydricum) 875mg, acidum clavulanicum (ut kalii clavulanas) 125mg. Augmentin Intravenous should not be mixed with blood products, other proteinaceous fluids such as protein hydrolysates or with intravenous lipid emulsions. If prescribed concomitantly with an aminoglycoside, the antibiotics should not be mixed in the syringe, intravenous fluid container or giving set because loss of activity of the aminoglycoside can occur under these conditions. Súhrn charakteristických vlastností lieku (SPC) AUGMENTIN 1 g tbl flm 1 g (blis.Al/PVC/PVDC) 1x14 ks. This page shows the Summary of Product Characteristics (SPC) and patient information leaflet (PIL) for the product. Before a medicine can be sold in the UK, a number of licences are essential.